Vu Nguyen, MD
Dermatopathology · Vista, CANPI 1588742555
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Pfizer at 36.5% of the total. Reporting peaked in 2019 at $572 and has fallen 85.6% since, to $83 in 2024.
Across 31 payments — averaging $28.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$321
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$92
- Bristol Myers Squibb$65
- LEO Pharma Inc.$64
- E.r. Squibb & Sons, L.L.C.$62
- Kaleo, Inc.$46
- plus $231 from 8 others
What the payments were for
- Food & beverage$881100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 16 | $321 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $92 |
| Bristol Myers Squibb | 1 | $65 |
| LEO Pharma Inc. | 1 | $64 |
| E.r. Squibb & Sons, L.L.C. | 1 | $62 |
| Kaleo, Inc. | 1 | $46 |
| Novartis | 2 | $45 |
| Lilly USA, LLC | 2 | $37 |
| Regeneron Healthcare Solutions, Inc. | 1 | $37 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Almirall LLC | 1 | $24 |
| Biofrontera Inc. | 1 | $22 |
| Strata Skin Sciences, Inc. | 1 | $21 |
| UCB, Inc. | 1 | $21 |
How this compares
$881 in reported general payments places this provider in the 65th percentile of 76 dermatopathology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Sensoready (2 Pens)Secukinumab | 19 | $83,276 |
| Calcipotriene | 203 | $30,240 |
| Clobetasol Propionate | 294 | $11,938 |
| Amjevita(Cf) AutoinjectorAdalimumab-Atto | 12 | $9,783 |
| Pimecrolimus | 19 | $8,142 |
| Fluorouracil | 213 | $8,089 |
| Tacrolimus | 86 | $7,759 |
| Triamcinolone Acetonide | 203 | $3,973 |
| Imiquimod | 114 | $3,847 |
| Ketoconazole | 167 | $2,716 |
| Mupirocin | 201 | $2,632 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 16 | $2,352 |
| Doxycycline Hyclate | 51 | $1,019 |
| Metronidazole | 60 | $993 |
| Clindamycin Phosphate | 27 | $953 |
Paid to pharmacies, not to this prescriber.
Other dermatopathology in Vista
- Christiane QuerfeldDuarte$107K
- Brittney de ClerckLos Angeles$56K
- Brook Brouhala Jolla$20K
- Vishwas ParekhDuarte$13K
- Susan Detwilerla Jolla$7K
- Mandy Ramanila Canada$7K
- Curt VogelEncinitas$7K
- Karen Sherwoodla Canada$6K
- John Honchla Canada$6K
- Stacy WhitelockFullerton$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.